XRTX Stock Chart & Stats
$2.22
>-$0.01(-0.25%)
At close: 4:00 PM EDT
$2.22
>-$0.01(-0.25%)
Day’s Range― - ―
52-Week Range$1.73 - $7.05
Previous Close$2.07
Volume18.14K
Average Volume (3M)12.60K
Market Cap
$4.51M
Enterprise Value$3.77
Total Cash (Recent Filing)$992.43K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.21
Shares Outstanding1,816,565
10 Day Avg. Volume12,766
30 Day Avg. Volume12,603
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$2.33M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces solvency risk and interest obligations, preserving financial flexibility while the company funds clinical development. This provides a stronger balance-sheet position than a highly leveraged development-stage biotech.
Focused Therapeutic PipelineA focused pipeline targeting kidney and metabolic disorders can concentrate research resources and clinical expertise around defined disease areas. Success in these programs could create a specialized platform, although commercial validation remains pending.
External Funding Supports DevelopmentA demonstrated ability to use equity financing has supported continued research and clinical development despite the absence of product revenue. This provides operational continuity, though future funding may depend on investor appetite and market access.
Bears Say
No Product RevenueThe absence of recurring product revenue means the company has not yet demonstrated commercial traction or a self-sustaining business model. Progress remains dependent on clinical milestones and eventual regulatory and market acceptance.
Persistent Operating LossesRecurring losses and negative gross profit show that operating expenses currently exceed any business income, with losses re-widening in the latest period. Profitability is unlikely to improve sustainably without successful development and commercialization.
Cash Burn And Dilution RiskPersistent cash consumption leaves the company reliant on external capital to fund trials and operations. Fluctuating equity alongside historical financing dependence creates ongoing dilution risk and could constrain development if capital becomes harder to raise.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $1.73 and its highest was $7.05 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is $4.51M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Nov 12, 2026 which is in 69 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Aug 15, 2026. The company reported -$1.05 earnings per share for the quarter.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -$1.05 in its last earnings report. Following the earnings report the stock price went down -9.686%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Technical Analysis
Ownership Overview
0.02%
Insiders
0.90% Other Institutional Investors
99.08% Public Companies and
Individual Investors